HomeTeam

Team of world-class scientists and highly experienced entrepreneurs and business leader

Our scientific team consists of  the leading global authorities on CA IX, including co-discoverers of CA IX, who have a combined joint expertise of more than 80 years on this topic.

Groundbreaking research on hypoxia has been a part of the subject for which the 2019 Nobel Prize for Medicine has been awarded; -three of our team members have co-authored recent studies on hypoxia and CA IX with one of its laureates, Sir. Peter J. Ratcliffe and still continue collaborating with him.

EXECUTIVE BOARD

Jaromir Pastorek
Jaromir Pastorek
Founder, Chief Scientific Officer and Chairman of the Scientific Board

Professor Jaromír Pastorek is an excellent Slovak biochemist, pedagogue, and discoverer of the gene encoding a protein CA IX which serves as an endogenous marker of hypoxia in tumors. At present, prof. Pastorek is a Principal Investigator at the Biomedical Research Center of Slovak Academy of Sciences (BMC SAS). Prof. Pastorek was the President of Slovak Academy of Sciences from 2009 until 2015. Formerly he also served as the Plenipotentiary of the Slovak Government for Research and Innovation.

Jaromír Pastorek is a Member of the Board of the Slovak Society for Biochemistry and Molecular Biology from 1998. He is the Member of the European Cancer Research Association (EACR), the Member of the Commission for the PhD degree in Molecular biology and Virology, the Elected member of the European Academy of Sciences and Arts (2008), and member of several others international scientific committees and organizations. He is the coinventor on US patent “MN Gene and Protein” (Zavada, Pastorekova, Pastorek) No. 5,384,676 issued in 1995 and on further 50 patents related to different aspect of MN protein (now named CA IX).

Prof. Pastorek’s research activities are focused on the identification and research of cancer diagnostic and therapeutic targets. His main scientific interest is the analysis of molecular mechanisms of adaptive response to hypoxia and acidosis during tumor development. He is a Principal Investigator of several research projects related to clinical use of CA IX. Prof. Pastorek has published over 185 papers, books, book chapters, and reviews.

Martin Bruncko
Martin Bruncko
Co-Founder and Acting CEO

Martin Bruncko is a technology entrepreneur, executive, investor, and former senior public policy leader. He has extensive expertise in building transformational deep tech companies, as well as from top echelons of national and international policymaking in the areas of finance and innovations.

He is also the founder and managing partner of Steam Capital and member of the investment committee of the European Innovation Council Fund, which is the largest deep tech investment fund in Europe.

Martin has held executive, board and advisory positions in several highly innovative, R&D-based companies. He was also the founder and executive chairman of Neulogy, the first major advisory and investment boutique in Central and Eastern Europe focusing on R&D, innovations and deep tech start-ups. Neulogy effectively kickstarted the tech ecosystem in Slovakia.

Previously, Martin held several senior positions in the Government of Slovakia, including junior minister for innovations and deputy for European affairs of the minister of finance. In this role, he was responsible for national policy in the area of knowledge economy, e-government and EU/Eurozone economic and financial affairs. He was also a Board Member of the European Stability Mechanism (previously EFSF) and  Senior Director and Head of Europe at the World Economic Forum.

Martin is also the founder of Druid Collective, a non-profit initiative of the World Economic Forum’s Young Global Leaders (YGLs) and Technology Pioneersfocused on helping exceptional start-ups around the world to bring breakthrough science from lab to impact.

He holds a B.A. from Stanford University and M.P.A. from Harvard Kennedy School. In 2012, he was honored as a Young Global Leader of the World Economic Forum.

ADVISORY BOARD

Adrian Harris
Adrian Harris

Cancer Research UK Professor of Medical Oncology at Oxford University, Editor-in-Chief of the British Journal of Cancer, Director of Cancer Research UK Molecular Oncology Laboratories at the Weatherall Institute of Molecular Medicine, Chairman of the CRUK Oxford Cancer Centre, joint lead of the Cancer theme of the Comprehensive Biomedical Research Centre in Oxford, fellow of the Academy of Medical Sciences

Giulio Superti-Furga
Giulio Superti-Furga

Scientific Director of the Research Center for Molecular Medicine of the Austrian Academy of Sciences, Professor of Medical Systems Biology at Medical University of Vienna, member of the Scientific Council of European Research Council, Founder of allcyte GmbH

Margaret Ashcroft
Margaret Ashcroft

Professor at the Department of Medicine at Cambridge University, Fellow of the Royal Society of Biology and Honorary Member of the Royal College of Radiologists

Silvia Pastorekova
Silvia Pastorekova

Director of the Biomedical Research Center of the Slovak Academy of Sciences